Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 31NIH 5NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Lymphoma 12Leukemia 12Neuroblastoma 8Multiple Myeloma 6Myelodysplastic Syndromes 5Central Nervous System Neoplasms 5Brain Neoplasms 5Lymphoma, Follicular 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Teratoma 3Neoplasms, Plasma Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Monocytic, Acute 3Immunoglobulin Light-chain Amyloidosis 3Congenital Abnormalities 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Recurrence 2Preleukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Neoplasms 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2

Interventions

Radiotherapy 3Methotrexate 3Cytarabine 3Cyclosporine 3Peripheral Blood Stem Cell Transplantation 2Daunorubicin 2Cyclophosphamide 2Busulfan 2zosuquidar trihydrochloride 1sargramostim 1merphos 1hydrocortisone hemisuccinate 1Whole-Body Irradiation 1Thioguanine 1Stem Cell Transplantation 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1Methoxsalen 1Idarubicin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Cyclosporins 1Colony-Stimulating Factors 1Asparaginase 1Antilymphocyte Serum 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Anemia, Refractory, with Excess of Blasts × Peripheral Blood Stem Cell Transplantation × Clear all
NCT00045305 2023-06-28

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Eastern Cooperative Oncology Group

Phase 2 Completed
17 enrolled 10 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00077116 2012-07-16

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
31 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡